Phase II study of rituximab in the treatment of cladribine-failed patients (pts.) with hairy cell leukemia (HCL).

被引：0
|
作者：
Nieva, J
Bethel, K
Baker, T
Saven, A
机构：
[1] Scripps Res Inst, Dept Pathol, La Jolla, CA USA
[2] Scripps Canc Ctr, La Jolla, CA USA
[3] Cecil H & Ida M Green Canc Ctr, La Jolla, CA USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1535
引用
收藏
页码：364A / 365A
页数：2
相关论文
共 50 条
  • [11] Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant
    Chihara, Dai
    Arons, Evgeny
    Stetler-Stevenson, Maryalice
    Yuan, Constance M.
    Wang, Hao-Wei
    Zhou, Hong
    Raffeld, Mark
    Xi, Liqiang
    Steinberg, Seth M.
    Feurtado, Julie
    James-Echenique, Lacey
    Wilson, Wyndham
    Braylan, Raul C.
    Calvo, Katherine R.
    Maric, Irina
    Dulau-Florea, Alina
    Kreitman, Robert J.
    BLOOD, 2019, 134
  • [12] Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
    Chihara, Dai
    Arons, Evgeny
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Wang, Hao-Wei
    Zhou, Hong
    Raffeld, Mark
    Xi, Liqiang
    Steinberg, Seth M.
    Feurtado, Julie
    James-Echenique, Lacey
    Tai, Chin-Hsien
    Patel, Keyur P.
    Braylan, Raul C.
    Calvo, Katherine R.
    Maric, Irina
    Dulau-Florea, Alina
    Kreitman, Robert J.
    BLOOD ADVANCES, 2021, 5 (23) : 4807 - 4816
  • [13] Long-term update of a phase II on the interest of rituximab with cladribine in the variant form of hairy cell leukemia
    Cailly, Laura
    Tomowiak, Cecile
    HEMATOLOGIE, 2022, 28 (01): : 10 - 12
  • [14] Pilot study of rituximab in refractory or relapsed hairy cell leukemia (HCL).
    Thomas, DA
    O'Brien, S
    Cortes, J
    Giles, FJ
    Koller, C
    Estey, E
    Kurzrock, R
    Faderl, S
    Pierce, S
    Keating, MJ
    Kantarjian, H
    BLOOD, 1999, 94 (10) : 705A - 705A
  • [15] Efficacy of Cladribine Combine With Rituximab versus Cladribine Alone in the Treatment of Hairy Cell Leukemia: A Retrospective Single-Center Study
    Acar, Ibrahim Halil
    Guvenc, Birol
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S323 - S324
  • [16] Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
    von Rohr, A
    Schmitz, SFH
    Tichelli, A
    Hess, U
    Piguet, D
    Wernli, M
    Frickhofen, N
    Konwalinka, G
    Zulian, G
    Ghielmini, M
    Rufener, B
    Racine, C
    Fey, MF
    Cerny, T
    Betticher, D
    Tobler, A
    ANNALS OF ONCOLOGY, 2002, 13 (10) : 1641 - 1649
  • [17] Treatment of hairy cell leukemia-variant (HCL-V) with cladribine.
    Tetreault, S
    Saven, A
    BLOOD, 1998, 92 (10) : 283B - 283B
  • [18] The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia
    Else, Monica
    Osuji, Nnenna
    Forconi, Francesco
    Dearden, Claire
    Del Giudice, Ilaria
    Matutes, Estella
    Wotherspoon, Andrew
    Lauria, Francesco
    Catovsky, Daniel
    CANCER, 2007, 110 (10) : 2240 - 2247
  • [19] Long term follow-up of patients with hairy cell leukemia (HCL) following cladribine treatment.
    Saven, A
    Burian, C
    Koziol, J
    Piro, L
    BLOOD, 1997, 90 (10) : 2573 - 2573
  • [20] Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC).
    Choueiri, T. K.
    Dreicer, R.
    Rini, B. I.
    Elson, P.
    Garcia, J.
    Mekhail, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 226S - 226S
12345